title: Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
abstract: Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than demonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, NY 14263, USA.
authors.forename: Taimur
authors.initials: T
authors.lastname: Sher
authors.forename: Kena C
authors.initials: KC
authors.lastname: Miller
authors.forename: David
authors.initials: D
authors.lastname: Lawrence
authors.forename: Amy
authors.initials: A
authors.lastname: Whitworth
authors.forename: Francisco
authors.initials: F
authors.lastname: Hernandez-Ilizaliturri
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Austin
authors.initials: A
authors.lastname: Miller
authors.forename: William
authors.initials: W
authors.lastname: Lawrence
authors.forename: Syed Ali
authors.initials: SA
authors.lastname: Bilgrami
authors.forename: Raman
authors.initials: R
authors.lastname: Sood
authors.forename: Margaret T
authors.initials: MT
authors.lastname: Wood
authors.forename: Annemarie W
authors.initials: AW
authors.lastname: Block
authors.forename: Kelvin
authors.initials: K
authors.lastname: Lee
authors.forename: Asher Alban
authors.initials: AA
authors.lastname: Chanan-Khan
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11; D002886:Chromosomes, Human, Pair 17; D003582:Cytogenetics; D018572:Disease-Free Survival; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide